Beactica Therapeutics

Beactica's platform integrates allosteric modulation, protein-protein interaction inhibition, and targeted protein degradation in a single molecular-interaction-based discovery engine built on SPR biosensor technology.

The company has a partner-validated track record, including TAK-831 advanced to Phase II by Takeda and a selective allosteric USP7 inhibitor outlicensed by Almac to Genentech, plus first-in-class degrader positioning in LSD1-CoREST and TEAD with FDA Orphan Drug Designation for BEA-17.

Glioblastoma affects approximately 35,000 people annually in the US and Europe, with median overall survival of about 15 months and five-year survival near 5 percent, leaving significant unmet medical need.

The targeted protein degradation field is expanding rapidly, and Beactica was named one of six TPD Companies to Watch 2025 by Clarivate. TEAD dysregulation is implicated in multiple cancer types, giving the degrader approach broad oncology applicability.

Beactica's Eclipsor platform generates proteolysis-targeting chimeras that recruit disease-causing proteins to E3 ligases for proteasomal destruction, enabling catalytic potency against previously undruggable targets.

Its lead programmes are BEA-17, a first-in-class LSD1-CoREST degrader with FDA Orphan Drug Designation for glioblastoma, and P65-047, a first-in-class TEAD transcription factor degrader for Hippo pathway-driven cancers.